GeneDx Holdings Corp Shares Surpass Analyst Target Price
Recently, shares of GeneDx Holdings Corp (Symbol: WGS) have surpassed the average 12-month analyst target price of $107.33, trading at $109.39 per share. When a stock meets or exceeds the target set by analysts, they typically have two options: downgrade the stock based on valuation or adjust the target price upward. Analyst reactions may also hinge on fundamental business developments that drive stock prices higher, prompting discussions about future target adjustments.
Within the Zacks coverage universe, six different analyst targets contribute to the average for GeneDx Holdings Corp. However, the average is merely a mathematical average. For instance, one analyst has set a lower target of $80.00, while another projects a much higher price of $135.00. The standard deviation among the targets is $18.832, highlighting the range of analyst opinions.
The average target price serves as a “wisdom of crowds” approach, drawing insights from multiple analysts rather than relying solely on one expert’s viewpoint. As WGS has crossed the average target price of $107.33, investors have a crucial opportunity to reassess the company’s stock. They must decide whether $107.33 is merely a temporary milestone before reaching an even higher target or if the current valuation suggests it may be prudent to consider taking profits.
Current Analyst Ratings for GeneDx Holdings Corp
| Recent WGS Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 3 | 3 | 3 | 3 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 3 | 3 | 3 | 3 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 2.0 | 2.0 | 2.0 | 2.0 |
The average rating reflected in the table is on a scale from 1 to 5, with 1 indicating a Strong Buy and 5 indicating a Strong Sell. This analysis utilized data provided by Zacks Investment Research via Quandl.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
